Clinical outcomes of a Phase II, multi-institutional Cesium-131 permanent prostate brachytherapy trial

      Purpose: The accrual of the first clinical trial using Cs-131 for permanent brachytherapy to treat early stage prostate cancer is 80% complete. Cesium has come into widespread use; the clinical results of this trial are mature enough to be of immediate, important practical use to practitioners.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect